Search all trials

Find therapies in clinical trials near you – page 10

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 968
countries: 28
conditions: 2 103

3 968 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Renal transplant

Not recruiting

Study on the Safety and Effectiveness of Regtivex and Tocilizumab in Patients Receiving HLA-Mismatched Living Donor Kidney Transplants

Registered drugNo placebo

Study on the Safety and Effectiveness of Regtivex and Tocilizumab in Patients Receiving HLA-Mismatched Living Donor Kidney Transplants

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Regtivex

Contact Research Centre

Small cell lung cancer limited stage

Not recruiting

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Argipressin

Contact Research Centre

Chronic lymphocytic leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Registered drugNo placebo

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

B-cell lymphoma recurrent+1

Not recruiting

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Registered drugNo placebo

Croatia

Participants:18–64 years · 65+ years
Substances:Acalabrutinib

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cevostamab

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bendamustine

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Lenalidomide

Contact Research Centre

Follicular lymphoma+2

Not recruiting

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Registered drugNo placebo

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Registered drugNo placebo

France

Participants:18–64 years
Substances:Ammonium Chloride Bp

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Carfilzomib

Contact Research Centre

Diffuse large B-cell lymphoma+3

Not recruiting

Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

Registered drugNo placebo

Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Allopurinol

Contact Research Centre

Mantle cell lymphoma refractory

Not recruiting

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acalabrutinib

Contact Research Centre

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Registered drugNo placebo

Austria

Participants:65+ years
Substances:Anakinra

Contact Research Centre

Find therapies in clinical trials near you – page 10

128 trials match your criteria

Renal transplant

Study on the Safety and Effectiveness of Regtivex and Tocilizumab in Patients Receiving HLA-Mismatched Living Donor Kidney Transplants

Small cell lung cancer limited stage

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Chronic lymphocytic leukaemia+2

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

B-cell lymphoma recurrent+1

Study on the Safety and Effectiveness of MB-CART2019.1 for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Plasma cell myeloma

Study on the Effectiveness and Safety of Cevostamab and Tocilizumab for Patients with Relapsed or Refractory Multiple Myeloma

Plasma cell myeloma

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Plasma cell myeloma

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Follicular lymphoma+2

Study of Axicabtagene Ciloleucel for Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Plasma cell myeloma

Study on the Safety and Effects of Forimtamig, Tocilizumab, and Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Diffuse large B-cell lymphoma+3

Study of Mosunetuzumab and Polatuzumab Vedotin Combination Treatment in Patients with B-Cell Non-Hodgkin Lymphoma

Mantle cell lymphoma refractory

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.